Evidence map›Paper›PMID 35295611›Full record

ArticlePathology oncology research : POR2022

Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers.

Virág Réka Szita, Gábor Mikala, András Kozma, János Fábián, Apor Hardi, Hussain Alizadeh, Péter Rajnics, László Rejtő, Tamás Szendrei, László Váróczy and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology oncology research : POR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Virág Réka SzitaDepartment of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
Gábor MikalaDepartment of Hematology and Stem Cell Transplantation, South Pest Central Hospital, National Institute for Haematology and Infectious Diseases, Budapest, Hungary.
András KozmaDepartment of Molecular Genetics, South Pest Central Hospital, National Institute for Haematology and Infectious Diseases, Budapest, Hungary.
János FábiánDepartment of Hematology and Stem Cell Transplantation, South Pest Central Hospital, National Institute for Haematology and Infectious Diseases, Budapest, Hungary.
Apor HardiDepartment of Hematology and Stem Cell Transplantation, South Pest Central Hospital, National Institute for Haematology and Infectious Diseases, Budapest, Hungary.
Hussain Alizadeh1st Department of Internal Medicine, University of Pécs, Pécs, Hungary.
Péter RajnicsDepartment of Haematology, Teaching Hospital Mór Kaposi, Kaposvár, Hungary.
László RejtőJósa András Teaching Hospital, Nyíregyháza, Hungary.
Tamás SzendreiTeaching Hospital Markusovszky, Szombathely, Hungary.
László VáróczyDepartment of Haematology, Faculty of Medicine, Clinical Center, University of Debrecen, Debrecen, Hungary.
Zsolt NagyDepartment of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
Árpád IllésDepartment of Haematology, Faculty of Medicine, Clinical Center, University of Debrecen, Debrecen, Hungary.
István Vályi-NagyDepartment of Hematology and Stem Cell Transplantation, South Pest Central Hospital, National Institute for Haematology and Infectious Diseases, Budapest, Hungary.
Tamás MassziDepartment of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
Gergely VargaDepartment of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
National Center for Epidemiology · HUSemmelweis University · HUUniversity of Pecs · HUJósa András Múzeum · HUMarkusovszky Egyetemi Oktatókórház · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the introduction of novel agents, multiple myeloma remains incurable for most patients, necessitating further therapeutic options. Venetoclax, a selective BCL-2 inhibitor, had shown promising results in patients with translocation t(11;14), but questions remain open about its optimal use. We have contacted all Hungarian haematology centers for their experience treating t(11;14) myeloma patients with venetoclax. 58 patients were reported. 37 received venetoclax in the relapsed/refractory setting with few or no other therapeutic options available. 21 patients started venetoclax as salvage after failing to achieve satisfactory response to first line therapy. In the relapsed/refractory setting objective response rate (ORR) was 94%, median progression-free survival (PFS) 10.0 months and median overall survival (OS) 14.6 months. In reinduction patients, ORR was 100%, median PFS and OS were not reached. Importantly, we found no adverse effect of high risk features such as deletion 17p or renal failure, in fact renal failure ameliorated in 42% of the cases, including three patients who became dialysis independent. Our study also reports the highest number of plasma cell leukemia cases successfully treated with venetoclax published in literature, with refractory plasma cell leukemia patients achieving a median PFS of 10.0 and a median OS of 12.2 months.

Indexed as

Multiple MyelomaBridged Bicyclo Compounds, HeterocyclicHumansHungarySulfonamidesBridged Bicyclo Compounds, HeterocyclicSulfonamidesvenetoclaxamyloidosismultiple myelomaplasma cell leukemiarelapsed/refractoryt(11;14)venetoclax

Identifiers

PMID35295611
PMCPMC8918485
OpenAlexW4214728090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.